Literature DB >> 17112775

F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma.

Jong Cheol Lee1, Jae Seung Kim, Jeong Hyun Lee, Soon Yuhl Nam, Seung-Ho Choi, Sang-Wook Lee, Sung-Bae Kim, Sang Yoon Kim.   

Abstract

In order to determine the efficacy and proper timing of routine PET scans for surveillance of recurrent head and neck squamous cell carcinoma (HNSCC), we evaluated the diagnostic performance of routine PET scans in relation to time interval from completion of treatment. Amongst 206 retrospectively evaluated post-treatment PET scans of 159 patients with HNSCC, 156 were performed for routine surveillance in subclinical cases. Diagnostic performance of PET scan and follow-up outcome were evaluated in relation to the time interval (2-6months, 6-12months, 12-24months, and >24months) of PET scan from the completion of treatment. Overall sensitivity and NPV of these PET scans for recurrence were 92.5% and 94.8%, compared with 55.0% and 76.9% for conventional evaluation methods. In the 156 routine scans, the diagnostic sensitivity, specificity, and NPV for locoregional recurrence were 90%, 91% and 97%, respectively, and the values for distant metastases and second primary cancers were 100%, 97% and 100%, respectively. The diagnostic accuracy of routine PET scans was not significantly altered by the time interval. Most (97%) of true negative cases on routine PET scans had no recurrence during a median 14months follow-up. PET scan may be a useful tool in routine surveillance for detection of recurrence in subclinical patients. For routine surveillance, the initial PET scan should be performed within 6months after completion of treatment and the proper timing of next routine PET scan for subclinical patient with initial negative PET result might be 1year after initial PET scan.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17112775     DOI: 10.1016/j.oraloncology.2006.08.006

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  12 in total

Review 1.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

2.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

Review 3.  Emerging biomarkers in head and neck cancer in the era of genomics.

Authors:  Hyunseok Kang; Ana Kiess; Christine H Chung
Journal:  Nat Rev Clin Oncol       Date:  2014-11-18       Impact factor: 66.675

4.  FDG-PET/CT in the surveillance of head and neck cancer following radiotherapy.

Authors:  Louise Madeleine Risør; Annika Loft; Anne Kiil Berthelsen; Frederik Cornelius Loft; Andreas Ruhvald Madsen; Ivan Richter Vogelius; Andreas Kjær; Jeppe Friborg
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-23       Impact factor: 2.503

Review 5.  Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma.

Authors:  Antoine Digonnet; Marc Hamoir; Guy Andry; Missak Haigentz; Robert P Takes; Carl E Silver; Dana M Hartl; Primož Strojan; Alessandra Rinaldo; Remco de Bree; Andreas Dietz; Vincent Grégoire; Vinidh Paleri; Johannes A Langendijk; Vincent Vander Poorten; Michael L Hinni; Juan P Rodrigo; Carlos Suárez; William M Mendenhall; Jochen A Werner; Eric M Genden; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-13       Impact factor: 2.503

Review 6.  Assessment of treatment response after chemoradiation of head and neck cancer.

Authors:  Fernando Luiz Dias
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

7.  Perceived value drives use of routine asymptomatic surveillance PET/CT by physicians who treat head and neck cancer.

Authors:  Benjamin R Roman; Shivangi Lohia; Nandita Mitra; Marilene B Wang; Anna M Pou; F Christopher Holsinger; David Myssiorek; David Goldenberg; David A Asch; Judy A Shea
Journal:  Head Neck       Date:  2020-01-10       Impact factor: 3.147

Review 8.  KSNM60 in Clinical Nuclear Oncology.

Authors:  Seung Hwan Moon; Young Seok Cho; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-08-31

9.  Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck.

Authors:  Lale Kostakoglu; Reza Fardanesh; Marshall Posner; Peter Som; Srikar Rao; Eunice Park; John Doucette; Evan G Stein; Vishal Gupta; Krzysztof Misiukiewicz; Eric Genden
Journal:  Oncologist       Date:  2013-09-13

10.  Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study.

Authors:  Ryul Kim; Chan-Young Ock; Bhumsuk Keam; Tae Min Kim; Jin Ho Kim; Jin Chul Paeng; Seong Keun Kwon; J Hun Hah; Tack-Kyun Kwon; Dong-Wan Kim; Hong-Gyun Wu; Myung-Whun Sung; Dae Seog Heo
Journal:  BMC Cancer       Date:  2016-02-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.